Clinical factors affecting the perception of hypoglycemia in type 1 diabetes patients treated with personal insulin pumps
More details
Hide details
Department and Chair of Metabolic Diseases, Jagiellonian University, Krakow, Poland
Ann Agric Environ Med. 2013;20(1):152–154
Introduction and Objective. The ability to perceive the symptoms of hypoglycemia during the early decrease in plasma glucose concentration may be critical for the safety of T1DM patients treated with intensive insulin therapy, including those treated with continuous subcutaneous insulin infusion (CSII). In the presented observational study an attempt was made to asses clinical factors that might affect subjective awareness of hypoglycemia in CSII-treated T1DM patients, with special attention to factors specific for this mode of treatment. Materials and Methods. For the purpose of the study, data of 110 CSII-treated T1DM patients were collected (78 females and 32 males). The records were analyzed from glucose meters (200-300 measurements/download, depending on meter type) and insulin pumps (total insulin dose, basal/bolus ratio, number of boluses/day, bolus calculator and dual wave/square bolus usage, continuous glucose monitoring data) from the last 3 years. Results. It was found that the level of subjective hypoglycemia perception inversely correlated with the number of hypoglycemic episodes per 100 measurements, age, duration of diabetes, time on insulin pump, and positively correlated with mean glycemia (n = 98; r = 0.22; p = 0.0286). With respect to CSII-related factors, hypoglycemia perception inversely correlated with the percentage of basal insulin (n = 106; r = -0.20; p = 0.0354). In stepwise regression analysis, independent predictors for impaired hypoglycemia perception were: age β = -0.29 (p = 0.023), duration of diabetes β = -0.24 (p = 0.029) and number of the hypoglycemia episodes for 100 measurements β = -0.33 (p = 0.0005). Conclusions. Risk factors for impaired hypoglycemia perception in CSII-treated patients include those identified previously for the general population of T1DM individuals. In addition, the presented results suggest that a higher basal/bolus ratio may lead to impairment of the ability to perceive early symptoms of hypoglycemia.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes. 1988; 37: 901-907.
Cryer PE. Hypoglycemia in diabetes mellitus. In Hypoglycemia: Pathophysiology, Diagnosis and Treatment. New York/Oxford, Oxford University Press. 1997: 91-125.
Deary IJ, Hepburn DA, MacLeod KM, Frier BM. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia. 1993; 36: 771-777.
Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol. 1992; 11(2): 135-8.
Ogundipe OO, Geddes J, Leckie AM, Frier BM. Impaired hypoglycaemia awareness and employment in people with Type 1 diabetes. OccupMed (Lond). 2011; 61(4): 241-6.
Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010; 1: CD005103.
Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002; 25: 593-598.
Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012; 26; 366(17): 1616-24.
Giménez M, Lara M, Conget I. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technol Ther. 2010; 12(7): 517-21.
Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. Diabet Med. 2007; 24(7): 778-83.
Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, et al. Meticulous prevention of hypoglycaemia normalizes the glycaemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycaemia in intensively treated patients with short- term IDDM. Diabetes. 1993; 42: 1683-1689.
Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycaemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994; 43: 1426-1434.
Ovalle F, Fanelli CG, Paramore DS, Hershey T, Craft S, Cryer PE. Brief Twice – Weekly Episodes of Hypoglycemia Reduce Detection of Clinical Hypoglycemia in Type 1 Diabetes Mellitus. Diabetes. 1998; 47: 1472-1479.
Philip E. Cryer. Hypoglycemia in Type 1 Diabetes Mellitus. Endocrinol Metab Clin North Am. 2010; 39(3): 641-654.
Hepburn DA, Patrick AW, Eadington DW, Ewing DJ, Frier BM. Unawareness of hypoglycaemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med. 1990; 7: 711-7.
Ooi C, Mullen P, Williams G. Insulin lispro: the ideal pump insulin for patients with severe hypoglycemic unawareness? Diabetes Care. 1999; 22(9): 1598-9.
Blasetti A, Di Giulio C, Tocco AM, Verrotti A, Tumini S, Chiarelli F, Altobelli E. Variables associated with severe hypoglycemia in children and adolescents with type 1 diabetes: a population-based study. Pediatr Diabetes. 2011; 12(1): 4-10.
Bachran R, Beyer P, Klinkert C, Heidtmann B, Rosenbauer J, Holl RW. German/Austrian DPV Initiative; German Pediatric CSII Working Group; BMBF Competence Network Diabetes. Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Pediatr Diabetes. 2012; 13(1): 1-5.
Matejko B, Cyganek K, Katra B, Galicka-Latala D, Grzanka M, Malecki MT, Klupa T. Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients. Rev Diabet Stud. 2011; 8(2): 254-8.